Biologically Active Small Molecules

A dual inhibitor of 5-LO and COX pathways, inhibiting 5-LO, COX-1, and COX-2 (IC₅₀s = 0.75 &muM, 0.65 &mug/ml, and 1.2 &mug/ml, respectively) may also inhibit other LO pathways in vivo.

BW A868C is a hydantoin compound that is structurally related to the DP receptor agonist BW 245C. BW A868C antagonizes the PGD2 and BW 245C-induced activation of human platelet adenylate cyclase.

BW A868C is a hydantoin compound that is structurally related to the DP receptor agonist BW 245C. BW A868C antagonizes the PGD2 and BW 245C-induced activation of human platelet adenylate cyclase.

BW A868C is a hydantoin compound that is structurally related to the DP receptor agonist BW 245C. BW A868C antagonizes the PGD2 and BW 245C-induced activation of human platelet adenylate cyclase.

A selective, nonpeptide CCR1 antagonist that can displace the endogenous CCR1 ligands, MIP-1&alpha, RANTES, and MCP-3 with Ki values of 1, 2.8, and 5.

A selective, nonpeptide CCR1 antagonist that can displace the endogenous CCR1 ligands, MIP-1&alpha, RANTES, and MCP-3 with Ki values of 1, 2.8, and 5.

A selective, nonpeptide CCR1 antagonist that can displace the endogenous CCR1 ligands, MIP-1&alpha, RANTES, and MCP-3 with Ki values of 1, 2.8, and 5.

A selective, nonpeptide CCR1 antagonist that can displace the endogenous CCR1 ligands, MIP-1&alpha, RANTES, and MCP-3 with Ki values of 1, 2.8, and 5.

A potent, ATP-competitive inhibitor of PDK1 in vitro (IC₅₀ = 11 nM) and in cells (IC₅₀ = 300 nM) also inhibits ERK8, MNK2, Aurora B, Aurora C, MARKs 1-4,TBK1, IKK&epsilon, and additional kinases at comparable concentrations.

A potent, ATP-competitive inhibitor of PDK1 in vitro (IC₅₀ = 11 nM) and in cells (IC₅₀ = 300 nM) also inhibits ERK8, MNK2, Aurora B, Aurora C, MARKs 1-4,TBK1, IKK&epsilon, and additional kinases at comparable concentrations.

A potent, ATP-competitive inhibitor of PDK1 in vitro (IC₅₀ = 11 nM) and in cells (IC₅₀ = 300 nM) also inhibits ERK8, MNK2, Aurora B, Aurora C, MARKs 1-4,TBK1, IKK&epsilon, and additional kinases at comparable concentrations.

A potent, ATP-competitive inhibitor of PDK1 in vitro (IC₅₀ = 11 nM) and in cells (IC₅₀ = 300 nM) also inhibits ERK8, MNK2, Aurora B, Aurora C, MARKs 1-4,TBK1, IKK&epsilon, and additional kinases at comparable concentrations.